8-K: Edwards Lifesciences Expands Portfolio with Strategic Acquisitions and Reports Mixed Q2 Results

Edwards Lifesciences announced the acquisition of JenaValve and Endotronix, while also reporting second quarter financial results with strong TMTT growth offset by lower-than-expected TAVR growth.

Summary

• Edwards Lifesciences reported its second quarter 2024 financial results, showing a 7% sales growth, or 8% on a constant currency basis.
• TAVR sales grew by 5%, or 6% on a constant currency basis, reaching $1.0 billion, but this was lower than expected.
• TMTT sales experienced significant growth of 75%, contributing $83 million in revenue, driven by the PASCAL system and early adoption of the EVOQUE system.
• The company's adjusted EPS was $0.70, which included a $0.04 benefit from a lower-than-expected tax rate.
• Edwards is lowering its full-year TAVR sales growth guidance to 5-7% from 8-10%, while increasing TMTT guidance to the higher end of $320 to $340 million.
• The company also announced the acquisition of JenaValve Technology and Endotronix for a total upfront purchase price of approximately $1.2 billion in cash, with up to an additional $445 million in milestone payments.
• The sale of the Critical Care business for $4.2 billion is expected to close in late Q3 2024.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the strategic acquisitions and strong TMTT growth, but tempered by the lower-than-expected TAVR growth and reduced guidance. The company is making strategic moves but faces some challenges.

Positives

• TMTT sales showed very strong growth, indicating success in this area.
• The company is expanding its portfolio through strategic acquisitions in aortic regurgitation and heart failure.
• The EVOQUE system is showing excellent clinical results, consistent with trial data.
• The company is actively pursuing significant opportunities to grow TAVR globally over the long term.
• The company is making progress with the National Coverage Decision process for transcatheter tricuspid valve replacement.
• The company has a strong cash position with $2.0 billion in cash, cash equivalents, and short-term investments.

Negatives

• TAVR sales growth was lower than expected, leading to a reduction in full-year guidance.
• The adjusted gross profit margin decreased slightly to 77.1% from 77.7% in the same period last year.
• Adjusted selling, general, and administrative expenses increased to $509 million, driven by expansion of field-based personnel.
• Adjusted research and development expenses increased to $303 million due to continued investments in transcatheter valve innovations.

Risks

• The acquisitions of JenaValve and Endotronix are subject to closing conditions and may not be completed.
• There are risks related to the integration of the acquired companies and their technologies.
• The company faces potential disruption to its ongoing business operations due to the acquisitions.
• There are potential transaction costs associated with the acquisitions.
• The company is subject to legal and regulatory risks related to the acquisitions.
• The company's future performance is subject to various market and economic risks.

Future Outlook

Edwards expects full-year 2024 sales growth of 8 to 10%, lowering TAVR guidance to 5 to 7% from 8 to 10%, and increasing TMTT guidance to the higher end of $320 to $340 million. The company expects minimal revenue contribution from the acquisitions in 2025. Q3 sales are expected to be $1.56 to $1.64 billion, and EPS is expected to be $0.67 to $0.71, assuming the inclusion of Critical Care and no impact from previously announced acquisitions.

Management Comments

• Bernard Zovighian, CEO, stated that second quarter total company sales growth of 8 percent reflected strong contributions from our rapidly growing TMTT product group, offset by lower-than-expected growth in TAVR.
• Mr. Zovighian also mentioned that Edwards is well-positioned to deliver sustainable TAVR growth in 2025 and beyond, driven by advancements in our leading SAPIEN platform, indication expansions to much larger populations of patients, and improving patient access to this important therapy.
• Mr. Zovighian stated that the company's vision for TMTT is becoming a reality, and their strategic commitment has developed into a growth portfolio of differentiated technologies.
• Mr. Zovighian said that the acquisitions expand the company's opportunities to address the unmet needs of aortic regurgitation and heart failure patients around the world.

Industry Context

The acquisitions of JenaValve and Endotronix demonstrate Edwards' strategic focus on expanding its presence in the structural heart market, particularly in areas with significant unmet needs like aortic regurgitation and heart failure. This move aligns with the broader industry trend of companies seeking to diversify their portfolios and address a wider range of cardiovascular conditions. The company is positioning itself to be a leader in the next frontier of aortic valve disease treatment.

Comparison to Industry Standards

• Edwards' TAVR growth of 5% is below the industry average for the quarter, with competitors such as Medtronic and Abbott reporting higher growth rates in their respective TAVR businesses.
• However, Edwards' TMTT growth of 75% significantly outpaces the industry average, indicating a strong competitive position in this emerging market.
• The acquisition of JenaValve positions Edwards to compete with companies like Abbott and Medtronic, who are also developing transcatheter solutions for aortic regurgitation.
• The acquisition of Endotronix allows Edwards to enter the heart failure management market, where companies like Boston Scientific and Abbott are already established players.
• Edwards' adjusted gross profit margin of 77.1% is in line with industry standards for medical device companies, but slightly lower than some of its direct competitors.

Stakeholder Impact

• Shareholders may experience short-term volatility due to the mixed financial results and acquisition announcements.
• Employees may experience changes due to the integration of the acquired companies.
• Customers may benefit from the expanded product portfolio and innovative technologies.
• Suppliers may see increased demand due to the company's growth.
• Creditors may see increased stability due to the company's strong cash position.

Next Steps

• The company will work to close the acquisitions of JenaValve and Endotronix.
• Edwards will focus on integrating the acquired companies and their technologies.
• The company will continue to pursue regulatory approvals for its products, including the JenaValve Trilogy Heart Valve System.
• Edwards will continue to engage with CMS on coverage for EVOQUE and the Cordella sensor.
• The company will present significant TAVR and TMTT clinical evidence at TCT in October 2024.
• The company will provide pro forma information for Q4 2024 when third quarter results are reported, reflecting the sale of Critical Care and the acquisitions.

Key Dates

Keywords

Edwards Lifesciences, TAVR, TMTT, JenaValve, Endotronix, Acquisition, Aortic Regurgitation, Heart Failure, Transcatheter Valve, Structural Heart, Cordella Sensor, Financial Results